2025年中,一场与华熙生物的“行业级舆论争议”将巨子生物推上了风口浪尖。 这场争端不仅是重组胶原蛋白与玻尿酸两大成分赛道的话语权之争,更让巨子生物卷入了旗下核心品牌“可复美”胶原蛋白含量虚标的舆论旋涡。 虽然这场风暴最终以检测标准不同得出的检测结果亦有差异落下了帷幕,但也在一定程度上对巨子生物的业绩造成影响。 叠加行业竞争日趋激烈,巨子生物交出了一份营收、利润双降的2025年成绩单:当期收入为...
Source Link2025年中,一场与华熙生物的“行业级舆论争议”将巨子生物推上了风口浪尖。 这场争端不仅是重组胶原蛋白与玻尿酸两大成分赛道的话语权之争,更让巨子生物卷入了旗下核心品牌“可复美”胶原蛋白含量虚标的舆论旋涡。 虽然这场风暴最终以检测标准不同得出的检测结果亦有差异落下了帷幕,但也在一定程度上对巨子生物的业绩造成影响。 叠加行业竞争日趋激烈,巨子生物交出了一份营收、利润双降的2025年成绩单:当期收入为...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.